Cliff Asness's FATE Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 1.16 M shares of Fate Therapeutics, Inc. (FATE) worth $1.14 M, representing 0.00% of the portfolio. First purchased in 2018-Q1, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in FATE, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 437,423 shares. Largest reduction occurred in Q2 2023, reducing 271,399 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Fate Therapeutics (FATE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Fate Therapeutics (FATE) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +30,591 | Add 2.70% | 1.16 M | $0.98 |
| Q3 2025 | +285,181 | Add 33.70% | 1.13 M | $1.26 |
| Q2 2025 | +261,208 | Add 44.65% | 846,233 | $1.12 |
| Q1 2025 | +437,423 | Add 296.35% | 585,025 | $0.79 |
| Q4 2024 | +123,518 | Add 512.86% | 147,602 | $1.65 |
| Q3 2024 | +7,624 | Add 46.32% | 24,084 | $3.50 |
| Q2 2024 | -5,638 | Reduce 25.51% | 16,460 | $3.28 |
| Q1 2024 | -212,960 | Reduce 90.60% | 22,098 | $7.34 |
| Q4 2023 | -97,853 | Reduce 29.39% | 235,058 | $3.74 |
| Q3 2023 | +332,911 | New Buy | 332,911 | $2.12 |
| Q2 2023 | -271,399 | Sold Out | 0 | $0.00 |
| Q1 2023 | +271,399 | New Buy | 271,399 | $5.70 |
| Q2 2022 | -15,438 | Sold Out | 0 | $0.00 |
| Q1 2022 | -11,393 | Reduce 42.46% | 15,438 | $38.80 |
| Q4 2021 | -9,301 | Reduce 25.74% | 26,831 | $58.51 |
| Q3 2021 | -1,992 | Reduce 5.23% | 36,132 | $59.28 |
| Q2 2021 | +4,277 | Add 12.64% | 38,124 | $86.80 |
| Q1 2021 | -1,475 | Reduce 4.18% | 33,847 | $82.46 |
| Q4 2020 | -5,184 | Reduce 12.80% | 35,322 | $90.93 |
| Q3 2020 | -8,979 | Reduce 18.14% | 40,506 | $39.97 |
| Q2 2020 | -2,994 | Reduce 5.71% | 49,485 | $34.31 |
| Q1 2020 | +33,393 | Add 174.96% | 52,479 | $22.22 |
| Q4 2019 | -10,493 | Reduce 35.47% | 19,086 | $19.60 |
| Q3 2019 | -403 | Reduce 1.34% | 29,579 | $15.52 |
| Q2 2019 | -3,790 | Reduce 11.22% | 29,982 | $20.31 |
| Q1 2019 | -5,042 | Reduce 12.99% | 33,772 | $17.56 |
| Q4 2018 | -8,393 | Reduce 17.78% | 38,814 | $12.83 |
| Q2 2018 | +15,170 | Add 47.35% | 47,207 | $11.33 |
| Q1 2018 | +32,037 | New Buy | 32,037 | $9.77 |
Cliff Asness's Fate Therapeutics Investment FAQs
Cliff Asness first purchased Fate Therapeutics, Inc. (FATE) in Q1 2018, acquiring 32,037 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Fate Therapeutics, Inc. (FATE) for 30 quarters since Q1 2018.
Cliff Asness's largest addition to Fate Therapeutics, Inc. (FATE) was in Q1 2025, adding 585,025 shares worth $462,228.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 1,162,005 shares of Fate Therapeutics, Inc. (FATE), valued at approximately $1.14 M.
As of the Q4 2025 filing, Fate Therapeutics, Inc. (FATE) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Fate Therapeutics, Inc. (FATE) was 1,162,005 shares, as reported at the end of Q4 2025.